Developing a synagis clinic for respiratory syncytial virus prophylaxis

Area of Science:

• Pediatrics
• Infectious Diseases
• Public Health

Background:

• Respiratory Syncytial Virus (RSV) poses significant risks to premature infants and children with chronic lung disease.
• Palivizumab (Synagis), a monoclonal antibody, is a key preventative measure against RSV infection in high-risk infants.
• Effective delivery of prophylaxis requires coordinated healthcare efforts.

Purpose of the Study:

• To describe the implementation and outcomes of a nurse-run ambulatory clinic for RSV prophylaxis.
• To evaluate the effectiveness of monthly palivizumab injections in a high-risk pediatric population.
• To assess the impact of coordinated care on RSV-related hospitalizations.

Main Methods:

• A nurse-managed ambulatory clinic administered monthly palivizumab injections over a 5-month RSV season.
• Coordination with community neonatal intensive care units was integral to patient recruitment and follow-up.
• Clinic outcomes were compared to published literature for similar patient cohorts.

Main Results:

• The clinic successfully provided RSV prophylaxis to 24 high-risk infants and their families each year for 2 years.
• RSV-related hospitalizations were reduced in the patient population served by the clinic.
• The duration of hospitalization for RSV-related events was also decreased.

Conclusions:

• A dedicated, nurse-run clinic model can effectively deliver RSV prophylaxis to high-risk infants.
• Inter-agency coordination is crucial for successful implementation of preventative health programs.
• This model demonstrates a positive impact on reducing the burden of RSV in vulnerable pediatric populations.